Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Teva-Medroxyprogesterone (02221284), Teva-Medroxyprogesterone (02221292), Teva-Medroxyprogesterone (02221306). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

MEDROXYPROGESTERONE ACETATE

Form:

10 of 10 products shown

7 general benefit · 1 not a benefit · 2 listing conditions apply

Other products in the same Health Canada class (G03A, G03AC, G03DA) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Norethindrone (Micronor): general benefit, Not a benefit
  • Progesterone (Prometrium): not a benefit
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

5 more in the class list below

AA-Medroxy · DIN 02244726 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Medroxy · DIN 02244726 Manufacturer: A A Pharma Inc.; listing date 2003-01-30 Health Canada: Marketed since 2024-11-15 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 2.5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Medroxy: Formulary list price $0.1301/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68715 · Verify on the e-Formulary ↗ (DIN 02244726)

Source record
DIN 02244726: AA-Medroxy Raw flags: sec3=Y Item: 683200069; group id 801; item number 1959; lccId None; manufacturer id AAP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1301; ministry $0.1301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244726 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68715
Interchangeable products
Provera · DIN 00708917 · $0.1301
Shortage status: resolved shortage (ended 2023-08-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244726
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Medroxy · DIN 02244727 · 5mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Medroxy · DIN 02244727 Manufacturer: A A Pharma Inc.; listing date 2003-01-30 Health Canada: Marketed since 2024-12-16 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Medroxy: Formulary list price $0.2602/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2602 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68716 · Verify on the e-Formulary ↗ (DIN 02244727)

Source record
DIN 02244727: AA-Medroxy Raw flags: sec3=Y Item: 683200011; group id 801; item number 1960; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.2602; ministry $0.2602 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244727 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68716
Interchangeable products
Provera · DIN 00030937 · $0.2602
Shortage status: resolved shortage (ended 2023-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244727
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Medroxy · DIN 02277298 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Medroxy · DIN 02277298 Manufacturer: A A Pharma Inc.; listing date 2007-03-09 Health Canada: Marketed since 2024-11-15 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 10 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Medroxy: Formulary list price $0.5649/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5649 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76294 · Verify on the e-Formulary ↗ (DIN 02277298)

Source record
DIN 02277298: AA-Medroxy Raw flags: sec3=Y Item: 683200061; group id 801; item number 1961; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.5649; ministry $0.5649 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277298 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76294
Interchangeable products
Provera · DIN 00729973 · $0.5649
Shortage status: resolved shortage (ended 2026-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02277298
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Medroxy · DIN 02267640 · 100mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Medroxy · DIN 02267640 Manufacturer: A A Pharma Inc.; listing date 2005-10-06 Health Canada: Marketed since 2024-12-16 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 100 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Medroxy: Formulary list price $1.2057/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2057 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75305 · Verify on the e-Formulary ↗ (DIN 02267640)

Source record
DIN 02267640: AA-Medroxy Raw flags: sec3=Y Item: 683200037; group id 801; item number 1962; lccId None; manufacturer id AAP Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $1.2057; ministry $1.2057 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02267640 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75305
Interchangeable products
Provera · DIN 00030945 · not recorded
Shortage status: resolved shortage (ended 2025-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02267640
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Provera · DIN 02523493 · 150mg/mL · injection solution-1mL pre-filled syringe

Temporary benefitMarketed · checked 2026-09-19
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Provera · DIN 02523493 Manufacturer: Pfizer Canada Inc.; listing date 2022-08-31 Health Canada: Marketed since 2022-04-25 · brand DEPO-PROVERA · ATC G03AC06 MEDROXYPROGESTERONE · form Suspension · route Intramuscular · ingredients MEDROXYPROGESTERONE ACETATE 150 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Provera: Formulary list price $34.7886/unit (unit not stated in source; not the patient's cost)

Ministry pays: $34.7886 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101256 · Verify on the e-Formulary ↗ (DIN 02523493)

Source record
DIN 02523493: Depo-Provera Raw flags: sec3c=Y Item: 683200118; group id 801; item number 1958; lccId None; manufacturer id PFI Source form: Inj Sol-1mL Pref Syr; strength: 150mg/mL Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $34.7886; ministry $34.7886 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523493 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101256
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02523493
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Provera · PIN 09858134 · 150mg/mL · injection solution-1mL pre-filled syringe

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Provera · DIN 09858134 Manufacturer: Pfizer Canada Inc.; listing date 2021-05-31 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Depo-Provera: Formulary list price $31.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $31.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858134)

Source record
DIN 09858134: Depo-Provera Raw flags: sec3c=Y Item: 683200117; group id 801; item number 1957; lccId None; manufacturer id PFI Source form: Inj Sol-1mL Pref Syr; strength: 150mg/mL Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $31.6900; ministry $31.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858134 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858134
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Provera · DIN 00708917 · 2.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued 2025-11-14 · checked 2026-09-18
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00708917 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 2.5MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 2.5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037 · Verify on the e-Formulary ↗ (DIN 00708917)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00708917). DIN 00708917: Provera Raw flags: dinStatus=E, sec3=Y Item: 683200069; group id 801; item number 1959; lccId None; manufacturer id PFI Source form: Tab; strength: 2.5mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.2567; ministry $0.1301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00708917 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037
Interchangeable products
AA-Medroxy · DIN 02244726 · $0.1301
Shortage status: discontinued (2025-08-14, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00708917
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.

Provera · DIN 00030937 · 5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued 2025-11-14 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00030937 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 5MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2602 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=430 · Verify on the e-Formulary ↗ (DIN 00030937)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00030937). DIN 00030937: Provera Raw flags: dinStatus=E, sec3=Y Item: 683200011; group id 801; item number 1960; lccId None; manufacturer id PFI Source form: Tab; strength: 5mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.5274; ministry $0.2602 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030937 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=430
Interchangeable products
AA-Medroxy · DIN 02244727 · $0.2602
Shortage status: discontinued (2025-07-03, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030937
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.

Provera · DIN 00729973 · 10mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued 2025-11-14 · checked 2026-09-18
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00729973 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 10MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 10 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5649 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7480 · Verify on the e-Formulary ↗ (DIN 00729973)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00729973). DIN 00729973: Provera Raw flags: dinStatus=E, sec3=Y Item: 683200061; group id 801; item number 1961; lccId None; manufacturer id PFI Source form: Tab; strength: 10mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $1.0271; ministry $0.5649 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00729973 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7480
Interchangeable products
AA-Medroxy · DIN 02277298 · $0.5649
Shortage status: discontinued (2025-09-22, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00729973
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.

Provera · DIN 00030945 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.Discontinued 2012-02-13 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00030945 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2012-02-13 · brand PROVERA 100MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Provera: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=675 · Verify on the e-Formulary ↗ (DIN 00030945)

Source record
DIN 00030945: Provera Raw flags: notABenefit=Y, sec3=Y Item: 683200037; group id 801; item number 1962; lccId None; manufacturer id PFI Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=675
Interchangeable products
AA-Medroxy · DIN 02267640 · $1.2057
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030945
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for: • Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and significantly reduce the risk of hyperplasia and carcinoma; • Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the absence of organic pathology; • Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial carcinoma; • Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women. For indications not including breast cancer, AA-MEDROXY should be prescribed only to women with intact uteri. 1.1. Pediatrics Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): see 7 Warnings and precautions, 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00085517.PDF PM date: 2026-07-24 Source product: AA-MEDROXY; DIN 02244726; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Provera · DIN 00708917 Shortage status: discontinued (2025-08-14, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00708917

Check this DIN again

Provera · DIN 00030937 Shortage status: discontinued (2025-07-03, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030937

Check this DIN again

Provera · DIN 00729973 Shortage status: discontinued (2025-09-22, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00729973

Check this DIN again

Other review policies

For Provera: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026